\n<\/p>\n
Biocytogen Unveils Innovative AI-Driven Antibody Discovery Platform<\/strong><\/p>\n On May 26, Biocytogen announced a significant advancement in antibody research with the launch of the RenSuper Workstation. This state-of-the-art platform uses artificial intelligence to streamline the process of discovering therapeutic antibodies, offering quick access to a vast library of human antibody sequences that have been rigorously tested.<\/p>\n The RenSuper Workstation, along with Biocytogen\u2019s High-Throughput Antibody Manufacturing Automation Centre, aims to enhance the efficiency of antibody validation and production. By incorporating Biocytogen\u2019s unique RenMice technology, this new system combines various elements of antibody discovery, including in vivo immune repertoires, AI-based candidate selection, and automated validation. This comprehensive approach promises to shorten the timelines and lower risks associated with developing monoclonal, bispecific, and other advanced antibody therapies.<\/p>\n The RenSuper Workstation revolutionizes the antibody discovery process. It shifts the traditional project-based methods to a more searchable and programmable format, allowing researchers to quickly pinpoint high-quality therapeutic candidates with a strong potential for development.<\/p>\n The platform offers immediate access to a comprehensive library of fully human antibodies targeting over 1,000 validated markers. Each of these comes with detailed data that helps researchers make informed decisions.<\/p>\n Equipped with AI models trained on over 100 million verified antibody sequences, RenSuper can efficiently select candidates for difficult biological targets. In tests using the RenNano platform, the AI reached a remarkable average hit rate of 46% and even hit peaks of 98%. This screening process not only identified promising candidates but also ensured an impressive 82% success rate for producing antibodies with high purity.<\/p>\n Every antibody selected by the AI undergoes a thorough validation process, including checks for binding, affinity, and specificity. This rigorous approach guarantees that the antibodies are reliable and ready for further development.<\/p>\n The RenSuper platform includes user-friendly features, allowing researchers to filter and compare antibody candidates based on various criteria, such as target and physicochemical characteristics. Additionally, it includes tools for rapid sequence assembly, accommodating various therapeutic formats.<\/p>\n Biocytogen\u2019s latest development marks a notable step forward in the field of antibody discovery, offering researchers the tools needed to make quicker and smarter choices in therapeutic development. With the RenSuper Workstation, the future of antibody therapy looks promising.<\/p>\n\n","protected":false},"excerpt":{"rendered":" Biocytogen Unveils Innovative AI-Driven Antibody Discovery Platform On May 26, Biocytogen announced a significant advancement in antibody research with the launch of the RenSuper Workstation. This state-of-the-art platform uses artificial intelligence to streamline the process of discovering therapeutic antibodies, offering quick access to a vast library of human antibody sequences that have been rigorously tested.<\/p>\n","protected":false},"author":1,"featured_media":32915,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_lock_modified_date":false,"footnotes":""},"categories":[30],"tags":[43150,2707,5428,43151,43152,5086,43153,114,43154,43155,1871,1872,43156,14310,118,43157,1839,43158,3982],"class_list":["post-32914","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business-news","tag-adc","tag-ai","tag-ai-powered","tag-antibodies","tag-antibody","tag-automation","tag-bispecifics","tag-business","tag-developability","tag-functional-relevance","tag-innovation","tag-investment","tag-monoclonal","tag-platform","tag-technology","tag-therapeutic","tag-wbo","tag-workstation","tag-world-business-outlook"],"_links":{"self":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/32914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/comments?post=32914"}],"version-history":[{"count":0,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/32914\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media\/32915"}],"wp:attachment":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media?parent=32914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/categories?post=32914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/tags?post=32914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}A New Standard for Therapeutic Antibody Discovery<\/h3>\n
Access to a Robust Antibody Library<\/h3>\n
AI-Enhanced Candidate Identification<\/h3>\n
Comprehensive Validation Process<\/h3>\n
Simplified Search and Design Features<\/h3>\n